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ABSTRACT 
Background β-2 and β-3 adrenergic receptors (ADRB2, ADRB3) are considered to play a role 
in energy expenditure and lipolysis. However the effects of the ADRB2 Gln27Glu and the 
ADRB3 Trp64Arg polymorphisms on weight loss are controversial. The aim of this study was 
to see the effect of these polymorphisms on the change of weight and body composition 
during a controlled weight loss program.  
Methods 173 healthy overweight and obese participants (91 women, 82 men) aged 18-50 
years participated in a 22 week-long intervention based on hypocaloric diet and exercise. 
They were randomized into four groups: strength, endurance, combined and physical activity 
recommendations. Body weight, body mass index (BMI) and body composition variables 
were assessed before and after the intervention. Genetic analysis was carried out according to 
standard protocols. 
Results No effect of the ADRB2 gene was shown on final weight, BMI or body composition, 
though Glu27 carriers of the supervised men group tended to reduce weight (p=0.019, 2.5 kg) 
and BMI (p=0.019, 0.88 kg) more than non-carriers. There seems to be an individual effect of 
the ADRB3 polymorphism on fat mass (p=0.004) and fat percentage (p=0.036), besides an 
interaction with exercise for fat mass (p=0.038). Carriers of the Arg64 allele had higher fat 
mass and fat percentage than non-carriers after the intervention (p=0.004, 2.8 kg). 
Conclusions The ADRB2 Gln27Glu and the ADRB3 Trp64Arg polymorphisms might 
influence weight loss and body composition, though the present evidence is weak, however 
further studies are necessary to clarify their roles. 
Key words: β-adrenergic receptors, weight loss, body composition, Gln27Glu and Trp64Arg, 
exercise and diet    
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INTRODUCTION 
The response to weight loss programs is influenced by genetic factors (Bouchard 2008; Loos 
and Rankinen 2005; Ordovas and Shen 2008), therefore it is essential to understand the 
genetic and biological background of obesity and weight loss processes in order to prevent 
and treat this complex disease. Energy balance is regulated by the adrenergic system (Blaak et 
al. 1993; Monroe et al. 2001), since both β-2 and β-3 adrenergic receptors (ADRB2, ADRB3) 
promote lipolysis and fat mobilization and modify glucose metabolism (Arner 1992; 
Enoksson et al. 2000; Hagstrom-Toft et al. 1998; Lafontan et al. 1997). The lipolysis function 
is even more important during exercise and energy restriction (Arner 1992; Arner 1995). 
Common polymorphisms, the Gln27Glu (Gln - Glutamine; Glu - Glutamic acid/ Glutamate) 
of the ADRB2 and the Trp64Arg (Trp – Tryptophan; Arg – Arginine) of the  ADRB3 genes, 
imply structural and functional differences among the protein versions thus can influence the 
control of body weight (Gagnon et al. 1996; Garenc et al. 2003; Green et al. 1995). 
Considering epidemiological studies of the ADRB2 gene, some have not found relationship 
between the Gln27Glu polymorphism and obesity related phenotypes (Bea et al. 2010; 
Echwald et al. 1998; Kortner et al. 1999; Rosado et al. 2015). While some researchers found 
that the Glu27 is the risk allele for obesity (Clement et al. 1995; Gonzalez Sanchez et al. 
2003; Lange et al. 2005; Large et al. 1997), on the contrary others reported that the Glu27 is 
the favorable allele, protective against obesity  (Meirhaeghe et al. 2000; Pereira et al. 2003). 
As for the ADRB3 gene, no association was shown in some cases between the Trp64Arg 
polymorphism and obesity (Bea et al. 2010; Gagnon et al. 1996), other studies showed the 
Trp64 allele is protective against the obesity (Clement et al. 1995; Corella et al. 2001; Ukkola 
et al. 2000; Widen et al. 1995).  
The interaction of the gene, physical activity and obesity has been suggested for both 
polymorphisms. Arner et al. found different effects of the Glu27 allele in sedentary and active 
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people (Arner 2000); differences in fat oxidation were reported between Glu27 and Gln27 
allele carriers in two studies (Macho-Azcarate et al. 2002; Rosado et al. 2015); Meirhaeghe et 
al. raised that physical activity can counteract the effect of the Gln27Glu polymorphism in 
weight control (Meirhaeghe et al. 1999), while for the ADRB3 gene Marti et al. observed 
different risk for obesity with the Trp64Arg polymorphism (Marti et al. 2002).  
Regarding interventional studies, as far as we know, none of them included both controlled 
exercise and diet program and the polymorphisms analyzed by us. In the case of the ADRB2 
gene, no significant main effect of the Gln27Glu polymorphism on changes in body weight or 
body composition after a program based resistance training in women (Bea et al. 2010), 
neither Rauhio et al. with a diet intervention, including weight maintenance (Rauhio et al. 
2013). However, in the HERITAGE study Glu27 carriers lost more body fat mass (Garenc et 
al. 2003). Applying only a diet intervention Ruiz et al. reported that the Glu27 allele carriers 
had greater reduction in body weight, body mass index (BMI) and lean mass in women (Ruiz 
et al. 2011). For the ADRB3 gene, previous studies showed no main individual effect of this 
polymorphism (Bea et al. 2010; Ukkola et al. 2003), however Bea et al. reported that within 
non-exercisers the carriers of the Arg64 allele gained greater percent body fat (Bea et al. 
2010). No differences were found in response to weight loss between Arg64 allele carriers 
and non-carriers in body weight and body fat, but the loss of visceral adipose tissue (VAT) 
was 43% lower in the Arg64 allele carriers (Tchernof et al. 2000). On the contrary, Phares et 
al. concluded that the Arg64 allele carriers have two times greater loss of percentage body fat 
(Phares et al. 2004). 
In contrast to the candidate gene studies, no genome-wide association studies (GWAS) 
showed associations with these polymorphisms on BMI, adiposity or fat distribution (Fox et 
al. 2012; Locke et al. 2015; Shungin et al. 2015; Speliotes et al. 2010), which questions the 
previous findings. To the best of our knowledge, there has been no GWA study carried out on 
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body composition changes during a weight loss program. Despite these controversies both 
polymorphisms are of interest in connection with obesity and weight loss. Consequently, the 
aim of the present study was to analyze the effect of two common polymorphisms, the 
ADRB2 Gln27Glu and the ADRB3 Trp64Arg on the changes of body weight, BMI and fat 
distribution during a highly controlled exercise and diet weight loss program and to examine 
the influence of these polymorphisms on baseline values for the mentioned parameters. 
METHODS  
The present study is the part of the RCT (ClinicalTrials.gov ID:  NCT01116856), Nutrition 
and Physical Activity Programs for Obesity Treatments, PRONAF (the PRONAF study 
according to its Spanish initials). The aim of the RCT was to assess the usefulness of different 
types of physical activity and nutrition programs for the treatment of adult obesity, and it was 
conducted in 2010 and 2011 following the ethical guidelines of the Declaration of Helsinki. 
The Human Research Review Committee of the University Hospital La Paz reviewed and 
approved the study design and the research protocol (code of approval PI-643). Further details 
of the study are described elsewhere (Zapico et al. 2012). 
  
Subjects  
The study participants were recruited through advertisements covering a wide variety of 
media (television, radio, press and Internet). A total of 2319 potential participants were 
informed about the nature of the study and those who were 18 to 50 years old, had a BMI 
between 25 and 34.9 kg/m2, were non-smokers, sedentary (i.e., two hours or less of structured 
exercise per week) (Brochu et al. 2009), and had glucose values <5.6 mmol/L (<100 mg/dL) 
(Rutter et al. 2012), were invited to participate in this study. Women with any disturbances in 
menstrual cycle were not eligible. Flow diagram of the participants and details on drop outs 
can be found elsewhere (Zapico et al. 2012). Participants provided written informed consent 
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prior to joining the study and completed a baseline assessment at the medical center, after 
which they were randomly assigned to groups. 
 
Study design  
The intervention was a 6-month diet and exercise-based program focusing on a behavior 
change. Participants entered into the study in two waves (overweight and obese phase), and 
were split into four randomly assigned groups, stratified by age and sex: strength (S), 
endurance (E), combined strength and endurance (SE) and the control groups (C) with 
physical activity recommendations. The measurements took place for all participants before 
starting, in week 1 and after 22 weeks of intervention, in week 24. Physical activity was 
assessed by a SenseWear Pro3 Armband™ accelerometer (Body Media, Pittsburgh, PA). 
Participants wore the monitor continuously for 5 days including weekends and weekdays 
following general recommendations (Murphy 2009). Daily energy expenditure was calculated 
using the Body Media propriety algorithm (Interview Research Software Version 6.0). 
Additionally, participants were asked to report physical activity habits and the amount of any 
food undertaken during the intervention through a personal diary. 
 
Diet intervention 
Before the intervention, negative energy balance was calculated for all participants taking into 
account their own daily energy expenditure based on accelerometry data and the 3-day food 
record, thus they followed an individualized hypo-caloric diet with a 25-30% caloric 
restriction (National Institutes of Health 1998). Macronutrient distribution was set according 
to the Spanish Society of Community Nutrition recommendations (Dapcich et al. 2004).  
 
Exercise intervention  
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All exercise training groups (S, E and SE) followed an individualized training program, which 
consisted of three times per week exercise sessions during 22 weeks, carefully supervised by 
certified personal trainers. Details of the different protocols developed by the groups are 
described elsewhere (Zapico et al. 2012). 
 
Control group 
Participants from the C group followed the dietary intervention and the physical activity 
recommendations of the American College of Sports Medicine (Donnelly et al. 2009), thus 
were advised to undertake at least 200-300 min of moderate-intensity physical activity per 
week. 
 
Adherence to diet was calculated as the estimated kilocalories (kcal) of the diet divided by the 
real kcal intake in percentage ([estimated kcal of diet/real kcal intake]x100), being 100% the 
highest adherence to it, following a methodology used previously (Acharya et al. 2009). 
Moreover, adherence to exercise was calculated by the number of sessions completed in 
regard to the theoretical sessions ([sessions performed/total sessions]x100). Assistance over 
90% of the training sessions (Hunter et al. 2000), and an adherence to diet over to 80% were 
required (Del Corral et al. 2009). 
 
Body composition  
Anthropometric measures included height (SECA stadiometer, Valencia, Spain, 0.01 m) and 
body weight (TANITA BC-420MA balance, Bio Lógica Tecnología Médica S.L, Barcelona, 
Spain, 0.1 kg). BMI was calculated as [body weight (kg)/(height (m2)]. Body composition (fat 
mass (kg), abdominal fat (kg), VAT (kg)) was assessed by dual-energy x-ray absorptiometry 
DXA (GE Lunar Prodigy; GE Healthcare, Madison, WI, GE Encore 2002, version 6.10.029 
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software) with an accuracy of 0.001 kg. Percentage body fat (% body fat) was calculated as 
[fat (kg)/ body weight (kg)*100%]. 
 
Genetic analysis  
Whole blood samples (5 ml) were collected in ethylene-diaminetetraacetic acid (EDTA) from 
each participant and sent to the laboratory for the analysis. Deoxyribonucleic acid (DNA) was 
extracted from each sample using the "QIAamp® DNA Blood Mini Kit" (QIAGEN Hilden, 
Germany) and the genotyping was performed for each single nucleotide polymorphism 
(SNP). For the overweight phase, the analysis of the ADRB2 Gln27Glu (rs1042714) and the 
ADRB3 Trp64Arg (rs4994) polymorphisms was done using polymerase chain reaction (PCR) 
and restriction fragment length polymorphism (RFLP) techniques described before (Clement 
et al. 1995; Large et al. 1997); and for the obese phase, the genotyping of the two 
polymorphisms was carried out using the corresponding TaqMan® SNP Genotyping Assays 
(Applied Biosystem, Foster City, CA, USA) with StepOne™ Real Time PCR System 
(Applied Biosystem, Foster City, CA, USA). 
Statistical analysis 
The statistical analysis was performed using IBM® SPSS® Statistics for Windows, Version 
22.0. (IBM Corp., Armonk, NY). Chi-square test was used to assess whether observed 
genotype frequencies were in the Hardy–Weinberg equilibrium (HWE). Normal distribution 
of each dependent variable was tested using Qunatile-Quantile plots, when needed Box-Cox 
transformation was applied using the optimal lambda value. Three genetic models (additive, 
dominant, recessive) were tested for the ADRB2 gene, however for the ADRB3 two groups 
(carriers and non-carriers Arg64 allele) were analyzed because of the low number of the 
homozygotes for the Arg64 allele. Based on exercise, the sample was divided in two groups: 
supervised (S, E, SE groups) as all protocols had the same characteristics (intensity, duration 
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and frequency) and non-supervised group (C group). Three-way (genotype x exercise type x 
sex) analysis of covariance (ANCOVA) was conducted using final values of weight and body 
composition parameters adjusted by age and initial values to reveal differences between 
genotype groups, men and women and exercise groups, as well possible interactions. Two-
way (genotype x sex) analysis of covariance (ANCOVA) was performed adjusted by age for 
BMI and percentage body fat at baseline to see initial differences between genotype groups 
and sexes. Statistical significance for post intervention comparisons was defined at the 
corrected alpha of 0.00179 for the ADRB2 and 0.00625 for the ADRB3 polymorphism, for 
baseline comparisons at 0.00357 for the ADRB2 and 0.0125 for the ADRB3 polymorphism 
with correction for repeated tests across the levels of the ANCOVA model factors, where 
appropriate. 
RESULTS 
The baseline characteristics of the 173 subjects who participated in the present study (after 
drop-outs, exclusions because of low adherence and missing data) are shown in Table 1. 
 
Table 1 about here. 
 
Genotype distributions and allele frequencies of the ADRB2 Gln27Glu polymorphism and 
ADRB3 Trp64Arg are shown in Table 2. Both genotype distributions were found in Hardy-
Weinberg equilibrium (p=0.987 for the ADRB2 and p=0.980 for the ADRB3 polymorphisms).  
 
Table 2 about here. 
 
ADRB2 Gln27Glu post-intervention comparisons  
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Results for the dominant model are shown as no significant results were found with the other 
models. According to this, it seems that this model is the one which fits the most to the 
behavior of this polymorphism. No main effect of the Gln27Glu polymorphism was observed 
for final body composition values adjusted by initial measurements, neither interaction with 
exercise, sex or both. Post hoc analyses revealed that within supervised men group, carriers of 
the Glu27 allele reduced weight and BMI more than non-carriers (p=0.019, 2.52 kg and 
p=0.019, 0.881 kg/m2 respectively; Figure 1). No differences were found for the other 
variables. (Figure 1 and 2). 
Figure 1 about here. 
Figure 2 about here. 
 
ADRB3 Trp64Arg post-intervention comparisons  
Regarding the Trp64arg polymorphism, no differences were seen for weight, BMI, android fat 
or VAT (Figure 3 and 4). The individual effect of the polymorphism was found for fat mass 
(p=0.004, F=8.519 (1)) and percentage fat (p=0.036, F=4.457 (1)), for fat mass reaching the 
corrected significance level. Moreover an interaction with exercise was observed for fat mass 
(p=0.038, F=4.383 (1)). Post hoc analyses indicated that Arg64 carriers had higher fat mass 
and fat percentage than non-carriers after the intervention (p=0.004, 2.82 kg and p=0.036, 
1.83% respectively). Moreover, the final fat mass of the female Arg64 carriers was 3.9 kg 
higher than the non-carriers (p=0.004), observing more specific differences depending on the 
genotype and type of exercise. The pair-wise comparison showed that the women carrying the 
Arg64 allele in the non-supervised exercise group had a higher final fat mass (p=0.004, 7.22 
kg) (Figure 4). Accordingly, among the Arg64 carriers in the whole sample and in women, the 
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supervised group reduced fat mass more than the non-supervised group (p=0.019, 4.31 kg and 
p=0.010, 6.59 kg respectively).  
Figure 3 about here 
Figure 4 about here 
Baseline  
Neither of the analyzed polymorphisms, the Gln27Glu of the ADRB2 or the Trp64Arg of the 
ADRB3 gene, showed main effect or interaction with sex or age for BMI or percentage body 
fat at baseline.  
 
DISCUSSION 
 
In the present work we studied the role of two polymorphisms of the beta-adrenergic 
receptors on body composition changes after a 24 week long diet and exercise intervention 
(supervised or non-supervised exercise) in healthy overweight and obese subjects. Our results 
suggest no strong influence of the ADRB2 Gln27Glu (rs1042714) and the ADRB3 Trp64Arg 
(rs4994) polymorphisms on these variables, but some associations were found, which could 
encourage us for further studies. 
Regarding the genotype distribution and allele frequencies of both polymorphisms in our 
sample were similar to the Iberian (IBS), European population (EUR) of the 1000 Genomes 
Project (Abecasis et al. 2012) and to previous studies on Spanish samples for the ADRB2 gene 
(Gonzalez Sanchez et al. 2003; Martinez et al. 2003), and for the ADRB3 gene (Corella et al. 
2001).  
As it was mentioned before, previous studies with Caucasians only included exercise protocol 
or diet but not both, therefore they are not fully comparable with our intervention. Even 
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though it is proved that in a weight loss program, diet drives to a higher loss than only 
exercise (Franz et al. 2007), yet the best protocols include both for further benefits (Clark 
2015; Curioni and Lourenco 2005). Moreover, the interaction between genes and physical 
activity was suggested by previous authors in connection with adrenergic receptor genes 
(Corbalan et al. 2002; Meirhaeghe et al. 1999; Phares et al. 2004). 
 
ADRB2 Gln27Glu post-intervention comparisons  
No main effect or interactions with other between-subject factors of the polymorphism were 
shown in our analyses for body composition parameters similarly to other studies based on 
weight loss programs (Bea et al. 2010; Phares et al. 2004; Rauhio et al. 2013). However, 
posthoc analyses revealed that supervised men carrying the Glu27 allele lost more weight and 
lowered BMI more (<0.05) than the Gln27Gln group, suggesting that supervised exercise and 
the Glu27 allele together in men can be beneficial to lose more weight. In previous studies of 
potential effect of this polymorphism on weight or BMI, also performed in Caucasian men 
subjects, was negative. Phares et al. applied a previous diet stabilization (but no caloric 
restriction) and aerobic training with subjects (age 50-75 years) with mean BMI of 27.8 
kg/m2, while the HERITAGE study only aerobic training with obese subjects, PRONAF 
consisted of a hypocaloric diet and exercise program. All three programs were between 20-24 
weeks long, our intensity was a bit lower than the other two programs´ (PRONAF 50%-60% 
of the HRR, Garenc et al. 55%-75% of the maximal oxygen consumption (VO2max), Phares 
et al. 50%-70% of the VO2max), however our sessions were longer (PRONAF 51.15-60 min, 
Garenc et al. 30-50 min, Phares et al. 20-40 min)(Garenc et al. 2003; Phares et al. 2004). 
Garenc et al. reported bigger fat mass changes in obese Glu27 homozygote men in the same 
study (Garenc et al. 2003), which were not confirmed in our study. As for women most of the 
studies did not confirm the importance of this polymorphism with only exercise or with only 
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diet (Bea et al. 2010; Rauhio et al. 2013; Rosado et al. 2015), which are in line with our 
negative results. Nevertheless Ruiz et al. reported after a low energy mixed diet with a very 
similar sample to ours that Glu27 carriers reduced more weight and BMI (Ruiz et al. 2011). 
The added feature in our study compared to this is the exercise, which could balance the 
differences reported by them, as no differences were found for weight or BMI. On the 
contrary the HERITAGE study found that Glu27Glu women reduced less the percentage fat 
than the other two groups in response to endurance training (Garenc et al. 2003). No 
differences were found for android fat or VAT in our analyses, but to the best of our 
knowledge no antecedents have been reported in the literature to the contrary (Bea et al. 2010; 
Rauhio et al. 2013; Ukkola et al. 2003).  
 
ADRB3 Trp64Arg post-intervention comparisons  
The individual effect of the Arg64 allele was observed for fat mass and percentage fat reached 
the 0.05 level, for fat mass even the corrected threshold. Moreover there was an interaction 
with exercise was found for fat mass. However the main effect of the Trp64Arg 
polymorphism was observed for the change of other body composition variables or any 
interaction with exercise or sex. Previous negative results disagree with our results on fat 
mass and fat percentage, but support the negative results of the other variables (Garenc et al. 
2001; Phares et al. 2004; Rawson et al. 2002; Ukkola et al. 2003). No differences were seen 
between carriers and non-carriers for weight or BMI what are in agreement with the other 
studies reporting the same after different weight loss interventions (hypocaloric diet, aerobic 
training, resistance training) with sedentary obese participants (Bea et al. 2010; Rawson et al. 
2002; Tchernof et al. 2000; Ukkola et al. 2003). Nevertheless, post hoc analyses showed that 
the carriers of the Arg64 allele lost less fat mass and reduced percentage fat less than non-
carriers during the intervention contrary to previous studies with a wide variety of protocols 
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(Garenc et al. 2001; Phares et al. 2004; Rawson et al. 2002; Tchernof et al. 2000; Ukkola et al. 
2003). Among the Arg64 carriers the non-supervised group had higher final fat mass values 
than the supervised group, which can suggest that supervised exercise is beneficent for the 
these genotypes. The interaction of this gene and physical activity was raised before. Marti et 
al. reported that this polymorphism means higher obesity risk in sedentary people than in 
active people (Marti et al. 2002), which was in line with the results of other group (Phares et 
al. 2004). Within women the carriers of the Arg64 allele lost less fat mass than the non-
carriers and non-supervised less fat mass than supervised subjects. Non-supervised Arg64 
carrier women had smaller reduction in fat mass than non-carriers, though this should be 
cautiously judged because this group was very limited, but it should be pointed out that it is in 
line with the findings of Marti et al (Marti et al. 2002).  Similarly, Bea et al. reported that after 
a 12 month-long resistance training program within the sedentary postmenopausal women 
(from normal weight to obese), Arg64 carriers gained significantly more percentage fat than 
non-carriers (Bea et al. 2010). As for android fat and VAT, differences were seen between 
carriers and non-carriers of the Arg64 allele. Conversely, Tchernof reported through a 13 
month long diet program that Arg64 carriers lost 43% less VAT than the Trp64Trp group 
(Tchernof et al. 2000). This intervention was much longer and from the dietary point of view 
stricter than ours which could have been determinant. 
The physiological changes of the receptor function caused by the gene variations together 
with the diet and exercise program could lead to divergent lipolysis rate and divergent amount 
of fat loss as a response to our program. However it is hard to state and confirm the 
underlying mechanisms of these differences for fat with our data as the project did not include 
deep physiological or molecular investigation. As it is well established adrenergic receptors 
play a role in fat mobilization and lipolysis (Arner 1992; Enoksson et al. 2000; Hagstrom-Toft 
et al. 1998; Lafontan et al. 1997) and this influence can be greater with exercise or diet (Arner 
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1992; Arner 1995). The interaction of these polymorphisms and physical activity has been 
studied too and it seems to exist, but still not clear (Arner 2000; Meirhaeghe et al. 1999; 
Rosado et al. 2015). Our and previous studies’ results are encouraging to further studies on 
this interaction. 
Baseline – Gln27Glu and Trp64Arg polymorphisms 
Our analyses showed no effect of the polymorphisms on BMI or percentage body fat or 
interaction of the polymorphisms and age or sex at baseline. Several studies, in agreement 
with our results, did not find association between the Gln27Glu polymorphism of the ADRB2 
gene and obesity or related parameters (Bea et al. 2010; Echwald et al. 1998; Kortner et al. 
1999). Most positive findings with the Gln27Glu polymorphism suggest that the favorable 
allele is the Gln27 allele, and the Glu27 allele contributes to obesity risk (Clement et al. 1995; 
Gonzalez Sanchez et al. 2003; Lange et al. 2005; Large et al. 1997). Contrary, other 
researchers showed that the Gln27 allele enhances the risk of obesity (Meirhaeghe et al. 2000; 
Pereira et al. 2003). As for the Trp64Arg polymorphism of the ADRB3 gene, no association 
was found in various studies in different populations (Bea et al. 2010; Gagnon et al. 1996), 
nevertheless the favorable feature of the Trp64 allele was demonstrated in the HERITAGE 
study and others (Clement et al. 1995; Corella et al. 2001; Ukkola et al. 2000; Widen et al. 
1995).  
As it is shown studies are not concordant. Part of the explication can be the study protocol, 
age and obesity status differences. Moreover previously it was suggested, that most candidate 
gene studies are underpowered, mainly because of the sample size and the lack of adjustment 
for multiple testing (Bray et al. 2009). Meta-analyses are in line with our results, reporting no 
associations with obesity and the ADRB2 Gln27Glu (Allison et al. 1998; Jalba et al. 2008), or 
ADRB3 Trp64Arg,(Kurokawa et al. 2008) in Europeans, though do confirm the importance in 
other races, Asians, Pacific Islanders, and American Indians. Studies using new techniques 
19	
	
(GWAS) also confirm the same (Fox et al. 2012; Locke et al. 2015; Shungin et al. 2015; 
Speliotes et al. 2010). 
A limitation of our work is the sample size, as the main objective of the study was not the 
exploration of the genetic background of the weight loss, thus this part of the study is 
underpowered. A correction for multiple testing was applied taking into account the 
polymorphisms, the genetic models, exercise groups and sexes, yet all results below 0.05 are 
reported and discussed. Another limitation of our study that there was no real control group 
for ethical reasons; all groups followed the individualized diet and the exercise programs or 
received physical activity recommendations. However the strength of our study is that both 
exercise and diet were included in the weight loss program, and were controlled by experts of 
the field.    
The conclusions of our study are that during an exercise plus diet program male carriers of the 
Glu27 allele of the ADRB2 Gln27Glu polymorphism might have advantage in lowering 
weight and BMI, and carriers of the Arg64 allele of the ADRB3 Trp64Arg polymorphism 
(especially women) might have difficulty in losing fat mass and percentage fat than the non-
carriers in Spanish overweight and obese population. However for Arg64 allele carriers 
supervised exercise can help to lose more fat mass compensating the effect of the allele, 
which gives promising practical use. Nevertheless the evidence is weak, thus more research is 
needed on this field with larger sample sizes and controlled protocols, taking into account all 
possible interactions among diet, exercise, genetic background and other factors. Finally, 
physical activity seems influence the effect of these polymorphisms during weight loss as it 
was suggested before.   
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Table 1. Baseline characteristics of the subjects 
BASELINE 
WOMEN 
ADRB2 ADRB3 
Glu27  
non-carrier 
(n=37) 
Glu27 carrier 
(n=54) 
Arg64  
non-carrier 
(n=76) 
Arg64 carrier 
(n=15) 
Age (years) 38.24±8.45 39.72±8.16 39.61±7.93 36.67±9.75 
Body weight (kg) 79.16±9.86 81.82±10.96 81.08±10.58 79.03±10.57 
BMI (kg/m2) 29.81±2.67 30.93±3.48 30.64±3.08 29.67±3.78 
Fat mass (kg) 34.17±5.19 35.63±7.1 35.3±6.37 33.78±6.73 
Fat percentage (%) 44.93±3.53 45.29±4.37 45.3±3.99 44.41±4.35 
Android fat (kg) 2.82±0.57 2.94±0.81 2.92±0.72 2.74±0.72 
VAT (kg) 0.71±0.34 0.79±0.38 0.77±0.35 0.69±0.44 
BASELINE 
MEN 
ADRB2 ADRB3 
Glu27  
non-carrier 
(n=28) 
Glu27 carrier 
(n=54) 
Arg64  
non-carrier 
(n=73) 
Arg64 carrier 
(n=9) 
Age (years) 39.39±7.15 39.78±8.82 39.88±8.09 37.78±9.74 
Body weight (kg) 97.02±11.47 95.45±10.39 95.86±10.24 97.03±14.84 
BMI (kg/m2) 31.27±2.46 30.78±2.85 30.91±2.6 31.25±3.67 
Fat mass (kg) 33.28±7.59 33.75±6.72 33.63±6.84 33.23±8.5 
Fat percentage (%) 35.48±4.78 36.82±4.75 36.49±4.73 35.29±5.32 
Android fat (kg) 3.43±0.96 3.44±0.93 3.46±0.88 3.24±1.31 
VAT (kg) 1.76±0.69 1.74±0.73 1.79±0.68 1.38±0.94 
Data presented as Mean ± Standard Deviation  
ADRB2, β-2 adrenergic receptor; ADRB3, β-3 adrenergic receptor; BMI, body mass index; 
VAT, visceral adipose tissue 
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Table 2. Genotype distribution and allele frequency of the ADRB2 and ADRB3 genes 
ADRB2 
 Gln27Gln Gln27Glu 
 
Glu27Glu 
 
Allele Gln27 
 
Allele Glu27 
All 65 (37.57%) 82 (47.40%) 26 (15.03%) 212 (0.61) 134 (0.39) 
Women 37 (40.65%) 40 (43.95%) 14 (15.4%) 114 (0.63) 68 (0.37) 
Men 28 (34.14%) 42 (51.22%) 12 (14.64%) 98 (0.60) 66 (0.40) 
ADRB3 
 Trp64Trp Trp64Arg 
 
Arg64Arg 
 
Allele Trp64 
 
Allele Arg64 
 All 148 (85.55%) 24 (13.87%) 1 (0.58%) 320 (0.92) 26 (0.08) 
Women 76 (83.52%) 15 (16.48%) 0 (0%) 167 (0.92) 15 (0.08) 
Men 72 (87.80%) 9 (10.98%) 1 (1.22%) 153 (0.93) 11 (0.07) 
Data presented as n (%) for genotypes and n (frequency) for alleles. 
ADRB2, β-2 adrenergic receptor; ADRB3, β-3 adrenergic receptors 
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Figure 1. β-2 adrenergic receptor (ADRB2) Gln27Glu polymorphism and weight and body 
composition variables after the intervention in men and women. Means of final values of 
Weight (a), Body mass index (BMI; b), Percentage body fat (fat %; c) are presented after 
adjustment for baseline values and age with 95% confidence intervals. * p < 0.05  
 
Figure 2. β-2 adrenergic receptor (ADRB2) Gln27Glu polymorphism and body composition 
variables after the intervention in men and women. Means of final values of Fat mass (a), 
Android fat (b), Visceral adipose tissue (VAT; c) are presented after adjustment for baseline 
values and age with 95% confidence intervals.  
Figure 3. β-3 adrenergic receptor (ADRB3) Trp64Arg polymorphism and weight and body 
composition variables after the intervention in men and women. Means of final values of 
Weight (a), Body mass index (BMI; b), Percentage body fat (fat %; c) are presented after 
adjustment for baseline values and age with 95% confidence intervals.  
 
Figure 4. β-3 adrenergic receptor (ADRB3) Trp64Arg polymorphism and body composition 
variables after the intervention in men and women. Means of final values of Fat mass (a), 
Android fat (b), Visceral adipose tissue (VAT; c) are presented after adjustment for baseline 
values and age with 95% confidence intervals. ** p<0.00625 
